Table 3.

Clinic characteristics as bivariate correlates of vaccine receipt in 91 clinics (n = 105,121).

	Adolescent vaccines				Childhood vaccines
	HPV, series initiation OR (95% CI)	HPV, series completion OR (95% CI)	Meningococcal conjugate OR (95% CI)	Tdap OR (95% CI)	Hepatitis B OR (95% CI)	MMR OR (95% CI)	Varicella OR (95% CI)
Female:male patient ratio	3.36 (2.08–5.42)***	2.16 (1.13–4.13)*	0.66 (0.29–1.51)	0.76 (0.55–1.04)	0.42 (0.18–1.03)	0.36 (0.14–0.94)*	0.13 (0.05–0.37)***
% White patients	0.96 (0.49–1.88)	1.13 (0.70–1.83)	0.54 (0.20–1.46)	1.04 (0.61–1.76)	0.74 (0.32–1.69)	0.55 (0.23–1.32)	0.44 (0.19–1.03)
% African-American patients	2.47 (1.18–5.15)*	1.19 (0.62–2.27)	1.34 (0.56–3.23)	0.82 (0.51–1.29)	1.54 (0.62–3.84)	1.45 (0.55–3.81)	0.83 (0.29–2.42)
% Hispanic patients	5.44 (0.91–32.73)	0.46 (0.13–1.64)	0.68 (0.11–4.42)	0.47 (0.13–1.68)	0.12 (0.02–0.75)*	0.07 (0.01–0.50)**	0.11 (0.01–1.22)
Patients with VFC-eligibility	1.11 (0.97–1.26)	1.05 (0.93–1.18)	1.14 (0.90–1.44)	1.02 (0.93–1.11)	1.50 (1.25–1.82)***	1.46 (1.19–1.78)***	1.21 (0.99–1.48)
Adolescent patient load	0.91 (0.80–1.04)	1.01 (0.91–1.12)	1.24 (0.97–1.58)	1.10 (0.94–1.28)	1.71 (1.45–2.01)***	1.79 (1.51–2.11)***	1.65 (1.39–1.94)***
Clinic specialty
Family medicine	(ref)	(ref)	(ref)	(ref)	(ref)	(ref)	(ref)
Pediatrics	0.70 (0.52–0.94)*	0.77 (0.59–1.01)	1.79 (1.25–2.55)**	1.22 (1.00–1.50)*	2.43 (1.69–3.49)***	2.51 (1.73–3.64)***	2.65 (1.80–3.91)***

Note. HPV = human papillomavirus; Tdap = tetanus, diphtheria, and pertussis booster; MMR = measles, mumps, and rubella; OR = odds ratio; 95% CI = 95% confidence interval; VFC = Vaccines for Children;

^*p < .05,

^**p < .01,

^***p < .001.

HPV vaccination assessed only among girls (n = 49,230). Outcomes for childhood vaccines refer to completion of the vaccine series (i.e., three doses of hepatitis B vaccine, two doses of MMR, and two doses of varicella).